Overview

Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801alone and With Pembrolizumab

Status:
Recruiting

Trial end date:
2023-11-30

Target enrollment:

Participant gender:

Summary

This Phase 1, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to ten study sites in the United States will participate in the study.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Linnaeus Therapeutics, Inc.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Antibodies
Pembrolizumab